Cell-free serum DNA in patients with bladder cancer: results of a prospective multicenter study

Anticancer Res. 2012 Aug;32(8):3119-24.

Abstract

Background/aim: Cell-free DNA may serve as a biomarker for patients with cancer; we designed our study to determine its potential in patients with bladder cancer (BCA).

Materials and methods: Short β-actin (ACTB)-106 and large ACTB-384 fragments were quantified using real time PCR (RT-PCR); the ratio of ACTB-384/ACTB-106 was defined as DNA integrity. We analyzed the serum from 95 patients with and from 132 without BCA.

Results: Patients with BCA had increased ACTB-106 levels and lower DNA integrity compared to patients without cancer. However, patients undergoing transurethral bladder resection (TURB) with histological exclusion of BCA had a similar ACTB-106 level and DNA integrity, as patients with BCA. Cell-free DNA was not correlated with smoker status, pT stage, grade or lymph node metastasis, or DNA integrity. There was a weak inverse correlation of age with DNA integrity in patients with BCA.

Conclusion: Analysis of serum cell-free DNA levels and fragmentation patterns are of limited value regarding the identification of patients with BCA.

Publication types

  • Multicenter Study

MeSH terms

  • Adult
  • Aged
  • Base Sequence
  • Case-Control Studies
  • Cell-Free System
  • DNA / blood*
  • DNA Primers
  • Female
  • Humans
  • Male
  • Middle Aged
  • Prospective Studies
  • Real-Time Polymerase Chain Reaction
  • Urinary Bladder Neoplasms / blood*
  • Urinary Bladder Neoplasms / genetics

Substances

  • DNA Primers
  • DNA